Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 12077563
Prefusion-stabilized hMPV F proteins
granted -
US 12076397
Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
granted -
US 12076328
Pharmaceutical compositions of niclosamide
granted -
US 12071436
Anti-parasitic compounds and uses thereof
granted -
US 12070444
Modulation of molecular markers using S-equol
granted -
US 12070472
Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
granted -
US 12070510
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
granted -
US 12070443
Methods of treating and preventing breast cancer with S-equol
granted -
US 12065490
Chimeric antigen receptors and methods of making
granted -
US 12064453
Biochemical and biomechanical conditioning for enhancing personalized mesenchymal stem cell therapies
granted -
US 12064511
Lipid nanoparticles containing silyl lipids for use in vaccines and gene therapy
granted -
US 12065489
Claudin-6 antibodies and drug conjugates
granted -
US 12064488
Nitroxide containing amyloid binding agents for imaging and therapeutic uses
granted -
US 12065412
CFTR regulators and methods of use thereof
granted -
US 12064413
Methods of treating melanoma with S-equol
granted -
US 12064502
Peptide exhibiting wrinkle-improving activity and uses thereof
granted -
US 12064476
Zika virus immunogenic compositions
granted -
US 12064512
Silyl lipids suitable for enhanced delivery of anti-viral therapeutics
granted -
US 12065479
Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof
granted -
US 12065416
cGAS antagonist compounds
granted -
US 12065485
Treatment of staphylococcal disorders
granted -
US 12060497
Coatings containing polymer modified enzyme for stable self-cleaning of organic stains
granted -
US 12059407
Compositions and methods for delivery of macromolecules
granted -
US 12059437
Methods and compositions for hematopoietic stem cell mobilization
granted -
US 12059474
Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
granted -
US 12060566
Self-inactivating lentiviral vector comprising a FOXP3 expression cassette
granted -
US 12060350
Therapeutic compounds and methods of use thereof
granted -
US 12053511
Cystatin C and Cystatin 9 to treat gut inflammation caused by thermal injury
granted -
US 12054517
Myeloid differentiation factor 2 (MD2) signaling and modulation
granted -
US 12053569
Indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells
granted -
US 12053455
Antigen-driven detection and treatment of coccidioidomycosis
granted -
US 12054744
NK cells exhibiting an adaptive phenotype and methods for preparing and for using
granted -
US 12053491
Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
granted -
US 12054483
Small molecule inhibitors of DYRK/CLK and uses thereof
granted -
US 12053494
Compositions comprising nanoparticles, method of making and uses thereof
granted -
US 12054607
Tough, healable composites displaying stress relaxation at the resin-filler interface
granted -
US 12055553
Method for diagnosing risk for inflammatory disease through glycan profiling
granted -
US 12049644
Platform for generating safe cell therapeutics
granted -
US 12048687
Methods of recruiting SDF-producing macrophages
granted -
US 12049642
Corneal endothelial cells with increased cell density and compositions thereof
granted -
US 12048710
Compositions and methods for modification of biomolecules
granted -
US 12050227
Lipid nanodisc formation by acryloyl-based copolymers
granted -
US 12043847
Compositions and methods for treating acne
granted -
US 12042529
Optimization of enzyme replacement therapy for treatment of homocystinuria
granted -
US 12043601
N-substituted-1H-1,2,4-triazole-3-carboxamides, analogues thereof, and methods of treatment using same
granted -
US 12042554
Compositions and methods for blocking ultraviolet radiation
granted -
US 12037390
Leptin antibodies and method of reducing leptin
granted -
US 12037374
Peptides, hydrogel compositions and methods of use thereof
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory